Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M142Revenue $M0.3Net Margin (%)-43,897.0Z-Score-0.2
Enterprise Value $M52.1EPS $-1.4Operating Margin %-46,697.0F-Score3
P/E(ttm))0Cash Flow Per Share $-0.9Pre-tax Margin (%)-43,896.0Higher ROA y-yN
Price/Book1.810-y EBITDA Growth Rate %-12.9Quick Ratio5.1Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %9.4Current Ratio5.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-57.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-78.1Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M55.7ROI % (ttm)-43.5Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 2.55-33%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 2.55-57%New holding, 81800 sh.81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.444.51view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.0623.79view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.7-5.56view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.61-2.3view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.58-1.16view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.67-4.49view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.511.59view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.52view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-50.39view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-49view

Press Releases about CYTR :

    Quarterly/Annual Reports about CYTR:

    News about CYTR:

    Articles On GuruFocus.com
    Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
    Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
    Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
    CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
    CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
    CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
    CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
    CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
    CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
    CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

    More From Other Websites
    Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ... Dec 15 2014
    CytRx Falls on Written FDA Notice for Aldoxorubicin Study Dec 04 2014
    CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical... Dec 03 2014
    CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical... Dec 03 2014
    CytRx to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 02 2014
    CytRx to Present at the Oppenheimer 25th Annual Healthcare Conference Dec 02 2014
    CytRx Falls on Partial Study Hold on Oncology Candidate Nov 19 2014
    FDA puts partial hold on CytRx cancer drug trials Nov 18 2014
    CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials Nov 18 2014
    CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials Nov 18 2014
    Amarantus passe un accord d’option exclusive pour l’acquisition auprès de Lonza d’un... Nov 17 2014
    CYTRX CORP Financials Nov 14 2014
    10-Q for CytRx Corp. Nov 06 2014
    CytRx Reports 2014 Third Quarter Financial Results Nov 04 2014
    CYTRX CORP Files SEC form 10-Q, Quarterly Report Nov 04 2014
    CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition Nov 04 2014
    CytRx Reports 2014 Third Quarter Financial Results Nov 04 2014
    CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium Oct 30 2014
    CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium Oct 30 2014
    CytRx Announces Publication of Preclinical Glioblastoma Data in Neoplasia Oct 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK